Lipton JH. Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit? Am J Hematol 2024 Aug 14. doi: 10.1002/ajh.27455.
PMID: 39140241